<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00166426</url>
  </required_header>
  <id_info>
    <org_study_id>526-02</org_study_id>
    <nct_id>NCT00166426</nct_id>
  </id_info>
  <brief_title>Exisulind Versus Placebo After Surgical Removal of the Prostate</brief_title>
  <official_title>Prospective, Randomized, Double-Blind Trial of Adjuvant Exisulind Versus Placebo for Patients at Risk for Prostate Cancer Recurrence After Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>OSI Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <brief_summary>
    <textblock>
      This is a study in which patients with prostate cancer treated by surgical removal of the
      prostate and considered to be at risk for prostate cancer recurrence will receive Exisulind
      250 mg twice a day or placebo twice a day for two years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess efficacy of drug vs placebo regarding overall rate of biochemical progression</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the efficacy of drug vs placebo regarding time to biochemical progression</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess efficacy of drug vs placebo regarding overall rate of clinical progression</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess efficacy of drug vs placebo regarding time to clinical progression</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess efficacy of drug vs placebo regarding cancer specific survival</measure>
  </primary_outcome>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exisulind</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Males 18 years of age or older with prostate cancer treated primarily by radical
        prostatectomy and randomized within 45 days after surgery may be eligible for enrollment
        into this protocol. Participants cannot have had hormonal therapy, cryotherapy,
        thermotherapy, or radiotherapy prior to entering the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bradley C. Leibovich, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>November 13, 2009</last_update_submitted>
  <last_update_submitted_qc>November 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulindac sulfone</mesh_term>
    <mesh_term>Sulindac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

